Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lilly Hopes To Score Novel Compounds Early By Offering To Screen Discoveries

This article was originally published in The Pink Sheet Daily

Executive Summary

Phenotypic Drug Discovery program is open to academia, private research labs and biotechs that could receive a report card or a deal.

You may also be interested in...



Big Data Poised To Change Pharma R&D, McKinsey Suggests

A McKinsey & Company white paper highlights the potential for big data gathered from across the health care spectrum to revolutionize pharma R&D.

Lilly In Collaboration To Screen NIH Pharmaceuticals Collection, Make Pharmacology Data Public

Repurposing opportunities are unlikely in this NCATS/Lilly project, which has the loftier goal of furthering understanding of how small molecule drugs actually work in complex human systems in order to improve drug development for the entire “research universe.”

Eli Lilly’s Open Source Approach To Early-Stage Research

Eli Lilly & Co., which like many big pharmas faces patent expiries and an uncertain late-stage pipeline, has worked to improve ties with the venture and academic communities to help spur access to early-stage and less expensive assets.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS069557

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel